Spinout from Nobel-winning Berkeley lab cuts cancer cell therapy deal with drug giant AbbVie
February 10, 2021 at 12:13 PM EST
The potential $300 million deal includes a cash and equity investment by AbbVie.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|